08-14 Eurofarma Laboratórios S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
05-15 Eurofarma Laboratórios S.A. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-26 Eurofarma Laboratórios S.A. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 CI
01-23 Bavarian Nordic A/S Signs Distribution Agreement with Eurofarma to Expand Access to Chikungunya Vaccine in Brazil CI
12-10 Psivant Therapeutics, Inc. announced that it has received $47.5 million in funding from YK Bioventures, Samsara BioCapital LLC, Roivant Sciences Ltd., LSV Capital Management, LLC, Eurofarma Laboratórios S.A. and other investors CI
11-14 Eurofarma Laboratórios S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
25-10-21 Mentis Care, Inc Appoints Hassan Kotob as Chief Executive Officer CI
25-10-21 SK Biopharmaceuticals Co., Ltd. Launches Joint Venture with Eurofarma for Ai-Based Epilepsy Management Platform CI
25-08-21 Eurofarma Laboratórios S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
25-05-15 Eurofarma Laboratórios S.A. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
25-03-26 Eurofarma Laboratórios S.A. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
25-03-16 Eurofarma Laboratórios S.A. acquired 60% stake in Klibra Agenciamento de Marcas e Negócios for approximately BRL 160 million. CI
24-11-14 Eurofarma Laboratórios S.A. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
Manager TitleAgeSince
Chief Executive Officer - 2021-11-22
Investor Relations Contact 40 2021-11-22
Director TitleAgeSince
Chairman - 2021-11-22
Director/Board Member 58 2021-11-22
Director/Board Member 50 2018-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
1/10/25 Buy 1,644,236 0.1665%
12/4/24 Sell 15,405,639 1.5600%
12/4/24 Buy 15,405,639 1.5600%

Financials

2024 2025
Net sales 10.97B 2.14B 1.87B 1.77B 1.6B 3B 205B 3.01B 21.02B 8.13B 104B 8.04B 7.86B 334B 12.48B 2.44B 2.12B 2.01B 1.82B 3.41B 234B 3.43B 23.9B 9.24B 119B 9.14B 8.94B 380B
Net income 117M 22.89M 19.94M 18.87M 17.13M 32.03M 2.2B 32.19M 225M 86.88M 1.11B 85.95M 84.06M 3.57B 571M 112M 97.18M 91.93M 83.48M 156M 10.7B 157M 1.09B 423M 5.43B 419M 410M 17.39B
Net Debt - -
  1. Stock Market
  2. Stocks
  3. EUFA3 Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!